Anumigilimab, Saline 0.9% clinical trials

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

This study is testing a new medicine called anumigilimab for adults with sickle cell disease. It's a key step to see if the medicine is safe and how the body reacts to it, compared to a dummy treatment. We're looking closely at any side effects and how healthy people are during the study.